Individual patient based meta-analysis of lentinan for unresectable/ recurrent gastric cancer

Anticancer Research

Volumn 29, Issue 7, 2009, Pages 2739-2745

  Oba, Koji ^a   Kobayashi, Michiya ^b   Matsui, Takanori ^c   Kodera, Yasuhiro ^d   Sakamoto, Junichi ^d  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KOCHI MEDICAL SCHOOL   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Advanced gastric cancer; Clinical trials; Lentinan; Meta analysis

Indexed keywords

FLUOROURACIL; LENTINAN; MITOMYCIN; TEGAFUR; UFT;

ADVANCED CANCER; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; LEUKOPENIA; LYMPH NODE METASTASIS; META ANALYSIS; MONOTHERAPY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; STOMACH CANCER; SYSTEMATIC REVIEW; THROMBOCYTOPENIA;

AGED; FEMALE; HUMANS; LENTINAN; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; STOMACH NEOPLASMS;

EID: 69249174129     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. GLOBOCAN database in International Agency for Research on Cancer. Available via http://www-dep.iarc.fr/ accessed February 04, 2009.
2. Sastre J, García-Saenz JA and Díaz-Rubio E: Chemotherapy for gastric cancer. World J Gastroenterol 12: 204-213, 2006.
3. Berardi R, Scartozzi M, Romagnoli E, Antognoli S and Cascinu S: Gastric cancer treatment: a systematic review. Oncol Rep 11: 911-916, 2004.
4. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A and Fleig WE: Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24: 2903-2909, 2006. (Pubitemid 46630593)
5. Wohrer SS, Raderer M and Hejna M: Palliative chemotherapy for advanced gastric cancer. Ann Oncol 15: 1585-1595, 2004. (Pubitemid 39567288)
6. Nakazato H, Koike A, Saji S, Ogawa N and Sakamoto J: Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet 343: 1122-1126, 1994. (Pubitemid 24142032)
7. Oba K, Teramukai S, Kobayashi M, Matsui T, Kodera Y and Sakamoto J: Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Cancer Immunol Immunother 56: 905-911, 2007. (Pubitemid 46729147)
8. Sakamoto J, Teramukai S, Nakazato H, Sato Y, Uchino J, Taguchi T et al: Efficacy of adjuvant immunochemotherapy with OK-432 for patients with curatively resected gastric cancer: a meta-analysis of centrally randomized controlled clinical trials. J Immunother 25: 405-412, 2002. (Pubitemid 43076892)
9. Popiela T, Zembala M, Oszacki J and Jedrychowski W: A follow-up study on chemoimmunotherapy (5-fluorouracil and BCG) in advanced gastric cancer. Cancer Immunol Immunother 13: 182-184, 1982. (Pubitemid 12032088)
10. Chihara G, Hamuro J, Maeda Y, Arai Y and Fukuoka F: Fractionation and purification of the polysaccharides with marked antitumor activity, especially lentinan, from Lentinus edodes (an edible mashroom). Cancer Res 30: 2776-2781, 1970.
11. Maeda Y and Chihara G: The effects of neonatal thymectomy on the antitumor activity of lentinan, carboxymethylpachymaran and zymosan, and their effects on various immune responses. Int J Cancer 11: 153-161, 1973.
12. Yoshino S, Watanabe H, Imano M, Yagi M, Suga T and Nakazawa S: Evaluation of efficacy for immune adjuvant (Lentinan (β-1, 3-glucan))-containing supplementary food in patients with unresectable and recurrent gastric cancer. Biotherapy 21: 265-273, 2007. (Pubitemid 47280279)
13. Odagiri Y, Masuyama T, Ohishi K, Suga T and Yasuda K: Safety trial for functional food containing superfine dispersed lentinan(β-1, 3-glucan) - trial of repetitive dosing ingestion in healthy adult volunteer -. Biotherapy 20: 578-589, 2006. (Pubitemid 46079551)
14. Nimura H, Mitsumori N, Takahashi N, Kashimura H, Takayama S, Kashiwagi H et al: S-1 combined with lentinan in patients with unresectable or recurrent gastric cancer. Jpn J Cancer Chemother 33: 106-109, 2006.
15. Kimura Y, Iijima S, Kato T, Tujie M, Naoi Y, Hayashi T et al: Usefulness of TS-1 and lentinan combination immunochemotherapy in advanced or recurrent gastric cancer - pilot study aiming at a randomized trial. Jpn J Cancer Chemother 30: 1125-1130, 2003.
16. Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K and Kumada K, for the Kanagawa lentinan research group: A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent disease: effect on prolongation of survival and improvement of quality of life. Hepatogastroenterology 46: 2662-2668, 1999.
17. Tanemura H, Saji S, Miya K, Tanaka S, Misawa K, Tsuchiya J et al: Clinical controlled study on significance of immunochemotherapy with lentinan for advanced or recurrent gastric cancer (final report). Biotherapy 10: 60-65, 1996. (Pubitemid 26068299)
18. Wakui A, Urushizaki I, Furue H, Taguchi T and Ogawa N: A randomized trial of tegafur alone versus tegafur plus lentinan in inoperable schirrhous gastric cancer. Biotherapy 7: 1224-1233, 1993.
19. Ochiai T, Isono K, Suzuki T, Koide Y, Gunji Y, Nagata M et al: Effect of immunotherapy with lentinan on patients' survival and immunological parameters in patients with advanced gastric cancer: results of a multi-centre randomized controlled study. Int J Immunother 8: 161-169, 1992. (Pubitemid 23023129)
20. Ebata T, Totsuka M, Uchino J, Kondo Y, Tanabe T, Katoh H et al: Clinical effects of lentinan on advanced gastric cancer - randomized controlled study. Biotherapy 5: 721-733, 1991.
21. Iwase H, Morise K, Kusugami K Inagaki T, Horiuchi Y, Ina K et al: A randomized controlled trial of UFT-mitomycin (UFT-M) chemotherapy and UFT-M plus lentinan therapy for advanced gastric cancer. Oncologia 24: 74-80, 1991.
22. Kameta C, Akazawa S, Miyoshi K, Tamiya M, Kondo Y, Kurosawa T et al: A clinical randomized controlled trial of lentinan. Biotherapy 4: 941-948, 1990.
23. Nishihara T, Akimoto M and Mori S: Anti-cancer effects of BRMs associated with nutrition in cancer patients. Jpn J Cancer Chemother 15: 1615-1620, 1988. (Pubitemid 18141281)
24. Taguchi T: Clinical efficacy of lentinan on patients with stomach cancer: end point results of a four-year follow-up survey. Cancer Detect Prev Suppl 1: 333-349, 1987.
25. Akimoto M, Nishihira T and Kasai M: Modulation of antitumor effect of BRM under various nutritional or endocrine conditions. Jpn J Cancer Chemother 13: 1270-1276, 1986. (Pubitemid 17180712)
26. Wakui A, Kasai M, Konno K, Abe R, Kanamaru R, Takahashi K et al: Randomized study of lentinan on patients with advanced gastric and colorectal cancer -Tohoku lentinan study group-. Jpn J Cance Chemother 13: 1050-1059, 1986. (Pubitemid 17217775)
27. Boku N, Yamamoto S, Shirao K, Doi T, Sawaki A, Koizumi W et al: Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer. (JCOG9912). Proc Am Soc Clin Oncol (abstr); p.LBA4513, 2007.
28. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M et al: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9: 215-221, 2008.
29. Oka M, for the Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC): The information of randomized phase III study of TS-1 alone versus TS-1 plus lentinan in advanced or recurrent gastric cancer (JFMC36-0701) registered in the UMIN Clinical Trials Registry (UMIN-CTR). Available via https://center.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action= brows&recptno=R000000696&type=summary&language=E) accessed February 04, 2009.
30. Shibata M, Nezu T, Fujisaki S, Andou K, Tomita R and Fukuzawa M: Clinical potential of biological response modifiers combined with chemotherapy for gastric cancer. Dig Surg 19: 255-260, 2002. (Pubitemid 35013723)
31. Sugiyama Y, Saji S and Ishihara K. Clinical and immunological evaluation of immunochemotherapy using low dose 5-FU/cisplatin and lentinan. Biotherapy 11: 1238-1244, 1997. (Pubitemid 28071060)